1.705

4.91% -0.085

Equillium Inc (EQ)

Overview News Price History Option Chain Discussions Forecast

Equillium Inc stock is currently priced at $1.705, with a 24-hour trading volume of 6,281. It has seen a -4.91% decreased in the last 24 hours and a -30.24% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $1.77 pivot point. If it approaches the $1.63 support level, significant changes may occur.

Previous Close:

$1.79

Open:

$1.79

24h Volume:

6,281

Market Cap:

$63.11M

Revenue:

Net Income/Loss:

$-8.22M

P/E Ratio:

-3.217

EPS:

-0.53

Net Cash Flow:

$11.59M

1W Performance:

-1.61%

1M Performance:

-30.24%

6M Performance:

+230.54%

1Y Performance:

+180.27%

1D Range:

$1.78

$1.8069

52W Range:

$0.45

$3.25

Equillium Inc Stock (EQ) Company Profile

Name

Equillium Inc

Sector

Healthcare (1201)

Industry

Biotechnology (688)

Phone

858 412 5302

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA

Employee

Twitter

Next Earnings Date

2024-05-22

Latest SEC Filings

EQ's Discussions on Twitter

Equillium Inc Stock (EQ) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-29-21	Resumed	Stifel	Buy
Sep-15-21	Initiated	Cantor Fitzgerald	Overweight
Jul-14-20	Reiterated	H.C. Wainwright	Buy
Jul-10-20	Resumed	Stifel	Buy
Feb-22-19	Initiated	SVB Leerink	Outperform

Equillium Inc Stock (EQ) Latest News

5 Stocks That More Than Doubled in Q1 With More Gains Ahead

Zacks Investment Research

Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

Benzinga

The Zacks Analyst Blog Highlights Janux Therapeutics, SoundHound, Root, Equillium and CleanSpark

Zacks Investment Research

Equillium Inc Stock (EQ) Financials Data

Equillium Inc (EQ) Net Income 2024

EQ net income (TTM) was -$8.22 million for the quarter ending September 30, 2023, a +89.16% increase year-over-year.

Equillium Inc (EQ) Cash Flow 2024

EQ recorded a free cash flow (TTM) of $11.59 million for the quarter ending September 30, 2023, a +124.73% increase year-over-year.

Equillium Inc (EQ) Earnings per Share 2024

EQ earnings per share (TTM) was -$0.24 for the quarter ending September 30, 2023, a +89.74% growth year-over-year.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.